Medical treatment of hyperthyroidism: State of the art

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 10, 2010, Pages 678-684

  Fumarola, A ^a   Di Fiore, A ^a   Dainelli, M ^a   Grani, G ^a   Calvanese, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Graves' disease; Hyperthyroidism; Thionamides

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; IODINE; LIOTHYRONINE; LITHIUM CARBONATE; METHYLPREDNISOLONE; POTASSIUM PERCHLORATE; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; RITUXIMAB; THIAMAZOLE; THYROID HORMONE; THYROTROPIN; THYROXINE;

ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTHRALGIA; ARTHRITIS; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DYSURIA; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LIVER FAILURE; LIVER TOXICITY; MAINTENANCE DRUG DOSE; NAUSEA; NONHUMAN; OBSTRUCTIVE JAUNDICE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; REVIEW; SERUM SICKNESS; SMELLING DISORDER; THROMBOCYTOPENIA; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TOXIC HEPATITIS; ULCERATIVE COLITIS; URTICARIA; VASCULITIS; VOMITING;

ANTITHYROID AGENTS; DRUG MONITORING; HUMANS; HYPERTHYROIDISM; METHIMAZOLE; RECURRENCE;

EID: 78349250217     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1253420     Document Type: Review

References (68)

1. Abraham P, Avenell A, Park CM, et al. A systematic review of drug therapy for Graves hyperthyroidism. Eur J Endocrinol 2005 153 489-498
2. Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990 70 675-679
3. Andersohn F, Konzen C, Garbe E. Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs. Ann Intern Med 2007 146 657-665
4. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007 146 25-33
5. Bahn RS, Burch HS, Cooper DS, et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009 19 7 673-674
6. Bandyopadhyay U, Biswas K, Banerjee RK. Extrathyroidal actions of antithyroid thionamides. Toxicol Lett 2002 128 117-127
7. Bauch K. Epidemiology of functional autonomy. Exp Clin Endocrinol Diabetes 1998 106 S16-S22
8. Berkman EM, Orlin JB, Wolfsdorf J. An anti-neutrophil antibody associated with a propylthiouracil-induced lupus-like syndrome. Transfusion 1983 23 135-138
9. Bonnema SJ, Bennedbaek FN, Gram J, et al. Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomised clinical trial. Eur J Endocrinol 2003 149 485-492
10. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003 14 520-535
11. Burch HB, Solomon BL, Cooper DS, et al. The effect of antithyroid drug pre-treatment on acute changes in thyroid hormone levels after 131I ablation for Graves disease. J Clin Endocrinol Metab 2001 86 3016-3021
12. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999 10 1525-1527
13. Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther 2007 20 277-287
14. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009 10 816-824
15. Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998 83 40-46
16. Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983 98 26-29
17. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009 94 6 1881-1882
18. Cooper DS. Antithyroid Drugs in the Management of Patients with Graves Disease: An Evidence-Based Approach to Therapeutic Controversies. J Clin Endocrinol Metab 2003 88 3474-3481
19. Cooper DS. Antithyroid drugs. N Engl J Med 2005 352 905-917
20. Cooper DS. The side-effects of antithyroid drugs. Endocrinologist 1999 9 457-467
21. DArcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001 44 1717-1718
22. Dasgupta S, Savage MW. Evaluation of management of Graves disease in District General Hospital: achievement of consensus guidelines. Int J Clin Pract 2005 59 1097-1100
23. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007 56 2715-2718
24. El Fassi D, Banga JP, Gilbert JA, et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009 130 252-258
25. El Fassi D, Clemmensen O, Nielsen CH, et al. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. J Clin Endocrinol Metab 2007 92 3762-3763
26. El Fassi D, Nielsen CH, Hasselbalch HC, et al. The rationale for B lymphocyte depletion in Graves disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006 154 623-632
27. El Fassi D, Nielsen CH, Kjeldsen J, et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves disease. Gut 2008 57 714-715
28. Fibbe WE, Claas FHJ, Van der Star-Dijkstra W, et al. Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br J Haematol 1986 64 363-373
29. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007 63 47-52
30. Garcia-Mayor RVG, Paramo C, Luna-Cano R, et al. Antithyroid drug and Graves hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest 1992 15 815-820
31. Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007 13 1365-1368
32. Gunton JE, Stiel J, Clifton-Bligh P, et al. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol. 2000 142 6 587
33. Heemstra KA, Toes RE, Sepers J, et al. Rituximab in relapsing Graves disease, a phase II study. Eur J Endocrinol 2008 159 609-615
34. Homsanit M, Sriussadaporn S, Vannasaeng S, et al. Efficacy of single the daily dosage of Methimazole vs. Propylthiuracil in the induction of euthyroidism. Clin Endocrinol (Oxf) 2001 54 385-390
35. Iagaru A, McDougall R. Treatment of Thyrotoxicosis. J Nucl Med 2007 48 379-389
36. Koenig RJ. Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 2005 15 835-840
37. Koornstra JJ, Kerstens MN, Hoving J, et al. Clinical and biochemical changes following 131I teraphy for hyperthyroidism in patients not pretreatred with antithyroid drugs. Neth J Med 1999 55 215-221
38. Kuehn BM. FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. JAMA 2009 302 4 369-371
39. Maugendre D, Gatel A, Campion L, et al. Antithyroid drugs and Graves diseaseprospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999 50 127-132
40. Mazza E, Carlini M, Flecchia D, et al. Long-term follow-up of patients with hyperthyroidism due to Graves disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs. continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008 31 866-872
41. McDermott MT, Kidd GS, Dodson LE Jr, et al. Radioiodine-induced thyroid storm. Case report and literature review. Am J Med 1983 75 353-359
42. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 16 2825-2833
43. Mitsiades N, Poulaki V, Tseleni-Balafouta S, et al. Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves disease. Thyroid 2000 10 527-532
44. Moriyama K, Tagami T, Usui T, et al. Antithyroid Drugs Inhibit Thyroid Hormone Receptor-Mediated Transcription. J Clin Endocrinol Metab 2007 92 1066-1072
45. Nakamura H, Noh JY, Itoh K, et al. Comparison of Methimazole and Propylthiouracil in Patient with Hyperthyroidism Caused by Graves Disease. J Clin Endocrinol Metab 2007 92 2157-2162
46. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006 35 663-686
47. Noh JY, Asari T, Hamada N, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 2001 May 54 5 651-654
48. Okamura K, Ikenoue H, Shiroozu A, et al. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves hyperthyroidism. J Clin Endocrinol Metab 1987 65 719-723
49. Papadakis KA, Rosenbloom B, Targan SR. Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology 2003 124 583
50. Pearce EN, Braderman LE. Hyperthyroidism: advantages and disadvantages of medical therapy. Surg Clin North Am 2004 84 833-847
51. Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ 2006 332 1369-1373
52. Ram R, Bonstein L, Gafter-Gvili A, et al. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am J Hematol 2009 84 247-250
53. Reinwein D, Benker G, Lazarus GH. A prospective randomised trial of antithyroid drugs dose in Graves disease therapy. J Clin Endocrinol Metab 1993 76 1516-1521
54. Rodien P. Rituximab in Graves disease. Eur J Endocrinol 2008 159 515-516
55. Roy G, Mugesh G. Bioinorganic chemistry in thyroid gland: effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. Bioinorg Chem Appl 2006 23214
56. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007 156 33-40
57. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007 66 143-150
58. Streetman DD, Khanderia U. Diagnosis and Treatment of Graves disease. Ann Pharmacother 2003 37 1100-1109
59. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 2004 14 459-462
60. Takagi S, Hummel BC, Walfish PG. Thionamides and arsenite inhibit specific T3 binding to the hepatic nuclear receptor. Biochem Cell Biol. 1990 68 616-621
61. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006 5 18-24
62. Toth EL, Mant MJ, Shivji S, et al. Propylthiouracil-induced agranulocytosis: an unusual presentation and a possible mechanism. Am J Med 1988 85 725-727
63. Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002 25 72-81
64. Volpe R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des 2001 7 451-460
65. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007 334 514-520
66. Wang PW, Luo SF, Huang BY, et al. Depressed natural killer activity in Graves disease and during antithyroid medication. Clin Endocrinol (Oxf) 1988 28 205-214
67. Weetman AP, Pickerill AP, Watson P, et al. Treatment of Graves disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med 1994 87 337-341
68. Zantut-Wittmann DE, Tambascia MA, da Silva Trevisan MA, et al. Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves disease. Thyroid 2001 11 575-580